CurrentBlue Cross Blue Shield - IowaPolicy 05.01.18

Subcutaneous Immune Globulin (SCIG) therapy

Policy governing medical necessity and prior authorization criteria for subcutaneous immune globulin products (SCIG) for FDA-approved indications and listed compendial uses for Wellmark Blue Cross and Blue Shield members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicySubcutaneous Immune Globulin (SCIG) therapy

Policy CodePolicy 05.01.18

Change TypeNo material changes

Effective DateMay 31, 2023

Next Review DateApr 1, 2024

Key ActionRequest prior authorization with indication-specific supporting data (e.g., IgG level, diagnostic tests) to obtain approval.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 monthstypical initial authorization length

1–3 moshorter initial authorizations

~20distinct indications listed

40+compendial uses

5listed HCPCS J-codes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coding and Laboratory Thresholds

Covered HCPCS/J-codes for SCIG productsHCPCSCovered

J1559	Injection, Immune Globulin (Hizentra), 100 mg
J1575	Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
J1555	Injection, Immune Globulin (Cuvitru), 100mg
J1558	Injection, immune globulin (Xembify), 100 mg
J1551	Injection, Cutaquig 100 mg

Laboratory thresholds — examples

IgG threshold for SCID/congenital agammaglobulinemiaPretreatment IgG < 200 mg/dL

IgG threshold for CVIDPretreatment IgG < 500 mg/dL or ≥ 2 standard deviations below the mean for age

IgG threshold for CLL prophylaxisPretreatment serum IgG < 500 mg/dL

IgG threshold for pediatric HIV and BMT/HSCT prophylaxisPretreatment serum IgG < 400 mg/dL (or age-adjusted 2 SD below mean where specified)

IgG threshold for HLH/MAS and other indicationsTotal IgG < 400 mg/dL or two standard deviations below the mean for age

Selective immunoglobulin thresholds

Selective IgA deficiency thresholdIgA level < 7 mg/dL with normal IgG and IgM levels

Selective IgM deficiency thresholdIgM level < 30 mg/dL with normal IgG and IgA levels

IgG subclass deficiency thresholdIgG1, IgG2, or IgG3 ≥ 2 standard deviations below mean for age on at least 2 occasions

Specific antibody deficiencyNormal total IgG, IgA and IgM with impaired specific antibody response

ITP platelet thresholds

Pediatric ITP (newly diagnosed) triggerSignificant bleeding symptoms, high risk for bleeding (see Appendix B), or need for rapid platelet increase

Adult ITP initial platelet thresholdPlatelet count < 30,000/mcL (or < 50,000/mcL with significant bleeding/high risk or need for rapid increase)

Chronic/persistent or refractory ITPPlatelet count < 30,000/mcL (or < 50,000/mcL with significant bleeding/high risk) and relapse or inadequate response/intolerance to corticosteroid or anti-D therapy

Serum IgG threshold

General serum IgG threshold for several indicationsTotal IgG < 400 mg/dL or two standard deviations below the mean for age

Requirement for re-authorization monitoringIgG trough levels monitored at least yearly and maintained at or above the lower range of normal for age

Use in HLH/MASIgG < 400 mg/dL or two SD below mean for age qualifies hypogammaglobulinemia treatment in HLH/MAS

IgG threshold

Common IgG threshold across multiple indicationsIgG < 400 mg/dL (or two standard deviations below mean for age)

CAR-T therapy-associated hypogammaglobulinemiaAuthorization may be granted for members with IgG < 400 mg/dL receiving CAR-T therapy

Secondary immunosuppressionAuthorization for secondary immunosuppression when IgG < 400 mg/dL

Platelet count (adult HIV-associated thrombocytopenia)

Adult HIV-associated thrombocytopenia platelet thresholdPlatelet count < 20,000/mcL

Documentation requirementsDocument significant bleeding and failure of RhIG in Rh-positive patients when applicable

Pediatric vs adult distinctionPediatric criteria require IgG < 400 mg/dL plus one listed condition; adult criteria focus on platelets <20,000/mcL with bleeding

T4 cell count

T4 (CD4) cell count criterion in pediatric HIV-associated thrombocytopeniaT4 cell count ≥ 200/mm3

Context of useOne of several pediatric criteria (in addition to IgG <400 mg/dL) qualifying for IG prophylaxis in HIV-infected children

DocumentationProvide T4 count as part of prior authorization documentation for pediatric HIV-associated thrombocytopenia

Provider Actions, Authorization & Documentation Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for the listed indications. Providers must verify member benefits and contract limitations prior to requesting authorization, as benefits may vary based on contract and exclusions may apply.

Prior authorization required with indication-specific criteria and specified initial authorization durations (see criteria sections).
Benefits may vary based on contract; verify member benefits and any exclusions prior to requesting prior authorization.
Initial authorization durations are commonly 1–6 months depending on indication; indication-specific durations are listed in the criteria section.
Continuation/reauthorization: members currently receiving IG must meet the applicable reauthorization criteria for their condition; requests for continuation that do not meet reauthorization or initial criteria may be denied as not medically necessary.

Documentation Required

Required Documentation

Submit diagnostic and clinical documentation specific to the requested indication to support medical necessity.

Provide relevant diagnostic test results (e.g., serum immunoglobulin levels IgG/IgA/IgM and IgG subclasses) and pre-treatment laboratory reports when applicable.
For primary immunodeficiency: include vaccine response to pneumococcal polysaccharide vaccine, genetic/molecular testing (if applicable), and lymphocyte subset enumeration by flow cytometry.
For continuation therapy in primary immunodeficiency: submit IgG trough levels (monitored at least yearly when applicable).
For CIDP and MMN: include pre-treatment electrodiagnostic studies (EMG/NCS); for CIDP include CSF analysis when available.
For dermatomyositis/polymyositis: include pre-treatment EMG and muscle biopsy report when available.
For autoimmune mucocutaneous blistering disease: provide biopsy and pathology report confirming diagnosis.
For myasthenia gravis and dermatomyositis/polymyositis: provide clinical records documenting standard treatments tried and failed.
For LEMS: provide neurophysiology studies and/or positive anti-P/Q voltage-gated calcium channel antibody test when applicable.

Documentation Required

Laboratory & Serologic Requirements

Certain indications require laboratory or serologic thresholds and documentation prior to authorization.

Laboratory threshold requirements: pretreatment serum IgG < 400 mg/dL is required for some prophylaxis indications (e.g., HIV pediatric prophylaxis, BMT/HSCT recipients, hypogammaglobulinemia from CAR-T therapy, secondary immunosuppression with IgG < 400 mg/dL).
Primary immunodeficiency thresholds: examples include pretreatment IgG < 500 mg/dL for CVID or IgG < 200 mg/dL for SCID (see criteria).
Serologic confirmation: anti-GAD antibody testing is required to confirm diagnosis for stiff-person syndrome; anti-P/Q type VGCC antibody testing may confirm LEMS.
HIV-associated thrombocytopenia: document platelet counts, bleeding severity, prior RhIG failure for Rh-positive patients, IgG levels (<400 mg/dL for pediatric criteria), history of infections or ART response, and T4 cell counts when applicable.
CAR-T therapy–related hypogammaglobulinemia: document ongoing CAR-T therapy and pretreatment serum IgG < 400 mg/dL.

Step Therapy

Step Therapy / Prior Treatment Documentation Required

Step therapy or documentation of prior standard therapies is required for several autoimmune and neurologic indications.

Document trials and failures, intolerance, or contraindications to standard first- and second-line therapies where required (e.g., myasthenia gravis: tried ≥2 standard therapies for refractory disease; dermatomyositis/polymyositis: corticosteroids and immunosuppressants tried and unsuccessful or not tolerated).
LEMS: documentation that anticholinesterases (e.g., pyridostigmine) and amifampridine (e.g., 3,4-diaminopyridine) were tried and unsuccessful or not tolerated.
Stiff-person syndrome: documentation of inadequate response to first-line treatment (benzodiazepines and/or baclofen).
Autoimmune mucocutaneous blistering disease and others: document failure or significant complications from standard treatments (e.g., corticosteroids, immunosuppressive agents).
ITP (chronic/persistent): provide records supporting trial and failure with corticosteroid or anti-D therapy unless contraindicated.

Prior Authorization

Continuation / Reauthorization Requirement

Continuation requests must meet applicable reauthorization criteria or will be treated as initial requests.

For conditions with listed reauthorization criteria: members currently receiving IG must meet those reauthorization criteria to continue therapy.
For conditions without specific reauthorization criteria: continuation for all members (including new members) requires meeting the initial authorization criteria.
Requests for continuation that do not meet the applicable reauthorization or initial criteria may be considered not medically necessary and denied.

Definitions and Product Examples

SCIG products (examples)

CutaquigImmune Globulin Subcutaneous (Human) — indicated for replacement therapy in primary humoral immunodeficiency (patients ≥ 2 years)

CuvitruImmune Globulin Subcutaneous (Human) — indicated for replacement therapy in primary humoral immunodeficiency (patients ≥ 2 years)

Hizentra, HyQvia, XembifyHizentra and HyQvia indicated for primary immunodeficiency (patients ≥ 2 years); Hizentra and HyQvia also have labeled CIDP maintenance indications; Xembify indicated for primary humoral immunodeficiency (patients ≥ 2 years)

Pretreatment serum IgG < 400 mg/dL

Pretreatment IgG < 400 mg/dL — pediatric HIV and BMT/HSCTPretreatment serum IgG < 400 mg/dL used to qualify pediatric HIV patients for primary prophylaxis and BMT/HSCT recipients when requested within first 100 days post-transplant or with IgG <400 mg/dL

Role in re-authorizationRe-authorization of 6 months may be granted when reduction in bacterial infections is demonstrated since initiation of IG therapy

Age considerationsPediatric HIV indications reference additional criteria (e.g., vaccine response, infections) in conjunction with IgG threshold

IgG < 400 mg/dL

IgG < 400 mg/dL used across indicationsIgG < 400 mg/dL is used as an authorization threshold for HLH/MAS, CAR-T-associated hypogammaglobulinemia, and secondary immunosuppression

Authorization durationTypically authorization for these indications is 6 months when criteria are met

DocumentationPretreatment IgG level must be documented in prior authorization request

Pediatric HIV-associated thrombocytopenia criteria

Pediatric HIV-associated thrombocytopenia — IgG requirementPediatric members require IgG < 400 mg/dL plus one of the listed conditions (e.g., ≥2 bacterial infections in 1 year, failed vaccine response, thrombocytopenia despite ART, chronic bronchiectasis, or T4 ≥ 200/mm3)

Authorization durationAuthorization of 6 months may be granted when pediatric criteria are met

DocumentationProvide IgG level and supporting evidence of the listed infection/vaccination/immune status condition with the prior authorization request

Impaired antibody response to pneumococcal polysaccharide vaccine

Impaired pneumococcal vaccine response — age limitFor age ≥ 2 years: impaired antibody response demonstrated to pneumococcal polysaccharide vaccine qualifies; not established for children < 2 years

ScopeUsed as part of criteria for primary immunodeficiency and other antibody deficiency diagnoses

ExclusionTherapy initiated in the hospital setting is excluded from this appendix' application

Risk factors for bleeding

Examples of bleeding risk factorsUndergoing procedures with anticipated blood loss, comorbidities (e.g., peptic ulcer disease, hypertension), mandated anticoagulation therapy, or professions/lifestyles with high trauma risk

Use in ITP criteriaAppendix B risk factors may justify IG use for rapid platelet increase or high bleeding risk in ITP

Not exhaustiveAppendix B provides examples and is not an exhaustive list of bleeding risk factors

OpenPayer

Subcutaneous Immune Globulin (SCIG) therapy

Coverage Criteria for SCIG

Coding and Laboratory Thresholds

Provider Actions, Authorization & Documentation Requirements

Background

Definitions and Product Examples